The FDA launched the final design of its Expedited IND Pilot and began accepting applications this week, aiming to shorten timelines from target selection to first-in-human studies. The program pairs drug sponsors with qualified research institutions to streamline IND application preparation and reduce procedural friction. FDA said applications will be accepted until Oct. 30, 2026, positioning the initiative as part of a broader push to keep U.S. trial start-up timelines competitive with China and Australia. The agency also incorporated public feedback on who qualifies to participate, according to coverage of the pilot’s rollout. Separately, the FDA also circulated details on how it is “weaving feedback” into the trial-pilot design, signaling that eligibility and submission mechanics may be tuned as stakeholders provide input during the initial run. For biopharma, the pilot is a practical test of whether IND pre-submission work can be standardized enough to compress development schedules without sacrificing safety review quality.